| Schedule of Presents Major Accounts of Statements of Operations |
The
following table presents major accounts of statements of operations by segments for the year ended December 31, 2025.
| | |
MDMOOC
Services | | |
Sales
of
patented
drugs | | |
Total | |
| Revenues | |
$ | 10,678,554 | | |
$ | 696,442 | | |
$ | 11,374,996 | |
| Cost of revenues | |
| (5,665,996 | ) | |
| (587,459 | ) | |
| (6,253,455 | ) |
| Selling and marketing expenses | |
| (1,539,487 | ) | |
| 48,893 | | |
| (1,490,594 | ) |
| General and administrative expenses | |
| (9,698,452 | ) | |
| (115,635 | ) | |
| (9,814,087 | ) |
| Research and development expenses | |
| (8,085 | ) | |
| - | | |
| (8,085 | ) |
| Total operating expenses | |
$ | (11,246,024 | ) | |
$ | (66,742 | ) | |
$ | (11,312,766 | ) |
| Segment
operating (loss) income | |
$ | (6,233,466 | ) | |
$ | 42,241 | | |
$ | (6,191,225 | ) |
| | |
| | | |
| | | |
| | |
| Interest income (expenses), net | |
| 343,149 | | |
| (21 | ) | |
| 343,128 | |
| Other income (expenses), net | |
| 45,333 | | |
| 34,079 | | |
| 79,412 | |
| Income tax benefits
(expenses) | |
| 42,957 | | |
| (89,139 | ) | |
| (46,182 | ) |
| Segment
net loss | |
$ | (5,802,027 | ) | |
$ | (12,840 | ) | |
$ | (5,814,867 | ) |
The
following table presents major accounts of statements of operations by segments for the year ended December 31, 2024.
| | |
MDMOOC
Services | | |
Sales
of
patented
drugs | | |
Total | |
| Revenues | |
$ | 13,712,964 | | |
$ | 2,151,809 | | |
$ | 15,864,773 | |
| Cost of revenues | |
| (5,510,088 | ) | |
| (1,442,472 | ) | |
| (6,952,560 | ) |
| Selling and marketing expenses | |
| (3,799,558 | ) | |
| (210,824 | ) | |
| (4,010,382 | ) |
| General and administrative expenses | |
| (4,815,975 | ) | |
| (174,672 | ) | |
| (4,990,647 | ) |
| Research and development expenses | |
| (252,451 | ) | |
| - | | |
| (252,451 | ) |
| Total operating expenses | |
$ | (8,867,984 | ) | |
$ | (385,496 | ) | |
$ | (9,253,480 | ) |
| Segment
operating (loss) income | |
$ | (665,108 | ) | |
$ | 323,841 | | |
$ | (341,267 | ) |
| | |
| | | |
| | | |
| | |
| Interest income, net | |
| 242,848 | | |
| 160 | | |
| 243,008 | |
| Other income, net | |
| 148,089 | | |
| 11,926 | | |
| 160,015 | |
| Income tax (expenses)
benefits | |
| (348,406 | ) | |
| 13,237 | | |
| (335,169 | ) |
| Segment
net (loss) income | |
$ | (622,577 | ) | |
$ | 349,164 | | |
$ | (273,413 | ) |
The
following table presents major accounts of statements of operations by segments for the year ended December 31, 2023.
| | |
MDMOOC
Services | | |
Sales
of patented drugs | | |
Total | |
| Revenues | |
$ | 10,406,734 | | |
$ | 9,027,211 | | |
$ | 19,433,945 | |
| Cost of revenues | |
| (5,162,438 | ) | |
| (5,759,315 | ) | |
| (10,921,753 | ) |
| Selling and marketing expenses | |
| (5,327,266 | ) | |
| (1,383,491 | ) | |
| (6,710,757 | ) |
| General and administrative expenses | |
| (6,470,944 | ) | |
| (226,365 | ) | |
| (6,697,309 | ) |
| Research and development expenses | |
| (514,411 | ) | |
| - | | |
| (514,411 | ) |
| Loss from disposal of property and equipment | |
| (1,719,442 | ) | |
| - | | |
| (1,719,442 | ) |
| Impairment of goodwill | |
| (5,617,865 | ) | |
| - | | |
| (5,617,865 | ) |
| Impairment of intangible
assets | |
| (536,206 | ) | |
| - | | |
| (536,206 | ) |
| Total operating expenses | |
$ | (20,186,134 | ) | |
$ | (1,609,856 | ) | |
$ | (21,795,990 | ) |
| Segment
operating (loss) income | |
$ | (14,941,838 | ) | |
$ | 1,658,040 | | |
$ | (13,283,798 | ) |
| | |
| | | |
| | | |
| | |
| Interest income, net | |
| 216,528 | | |
| 20,526 | | |
| 237,054 | |
| Other income, net | |
| 1,069,603 | | |
| 142 | | |
| 1,069,745 | |
| Income tax benefits
(expenses) | |
| 700,048 | | |
| (30,288 | ) | |
| 669,760 | |
| Segment
net (loss) income | |
$ | (12,955,659 | ) | |
$ | 1,648,420 | | |
$ | (11,307,239 | ) |
|